Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986231 in Healthy Volunteers
NCT02819271Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing BMS-986231 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 31 days and Tolerability measured by percentage of Treatment Emergent Adverse Events at 31 days. Started Feb 2014; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02819271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819271.